Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lonks, J. R.
Right arrow Articles by Medeiros, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lonks, J. R.
Right arrow Articles by Medeiros, A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 87-92
© 2002 The British Society for Antimicrobial Chemotherapy

Supplement

Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides

J. R. Lonks*, J. Garau and A. A. Medeiros

1 Brown Medical School and the Miriam Hospital, Providence, RI, USA; 2 Hospital Mutua de Terrassa, Barcelona, Spain

Abstract

Macrolide resistance among pneumococci is increasing worldwide and is associated with increasing macrolide use. Recent studies show that use of macrolides and azalides increases nasopharyngeal carriage of both macrolide-resistant and penicillin-resistant pneumococci. Carriage of a resistant pneumococcus may foster dissemination. The clinical relevance of in vitro resistance has been debated. However, recent data from a matched case–control study showed that 18 (24%) of 76 patients had breakthrough bacteraemia with an erythromycin-resistant pneumococcus while taking a macrolide, whereas none of the 136 matched controls with an erythromycin-susceptible pneumococcal bacteraemia was taking a macrolide (P = 0.0000001). Moreover, five (24%) of 21 patients bacteraemic with the low-level resistant M phenotype and none of the 40 matched controls were taking a macrolide (P = 0.00157). These data indicate that macrolide resistance due to both the efflux and the methylase mechanisms is clinically relevant. Furthermore, they favour guidelines for the empirical treatment of outpatients with community-acquired pneumonia that recommend high-dose oral amoxicillin and reserve coverage of atypical pathogens for selected high-risk populations.

Footnotes

* Correspondence address. Division of Infectious Diseases, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA. Tel: +1-401-793-4620; Fax: +1-401-793-4534; E-mail: John_Lonks{at}brown.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. Martin, S. Quilici, T. File, J. Garau, A. Kureishi, and M. Kubin
Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance
J. Antimicrob. Chemother., May 1, 2007; 59(5): 977 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Yasuda, K. Kasahara, F. Mizuno, K. Nishi, K. Mikasa, and E. Kita
Roxithromycin Favorably Modifies the Initial Phase of Resistance against Infection with Macrolide-Resistant Streptococcus pneumoniae in a Murine Pneumonia Model
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1741 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Cassone, M. M. D'Andrea, F. Iannelli, M. R. Oggioni, G. M. Rossolini, and G. Pozzi
DNA microarray for detection of macrolide resistance genes.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2038 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Y. Fukuda, K. Yanagihara, Y. Higashiyama, Y. Miyazaki, Y. Hirakata, H. Mukae, K. Tomono, Y. Mizuta, K. Tsukamoto, and S. Kohno
Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae
Eur. Respir. J., May 1, 2006; 27(5): 1020 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
I. Brook and J. N. Hausfeld
Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis.
Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 442 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J.-H. Song, S.-I. Jung, K. S. Ko, N. Y. Kim, J. S. Son, H.-H. Chang, H. K. Ki, W. S. Oh, J. Y. Suh, K. R. Peck, et al.
High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study)
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2101 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J.-H. Song, H.-H. Chang, J. Y. Suh, K. S. Ko, S.-I. Jung, W. S. Oh, K. R. Peck, N. Y. Lee, Y. Yang, A. Chongthaleong, et al.
Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP)
J. Antimicrob. Chemother., March 1, 2004; 53(3): 457 - 463.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.